# FDA extends Casgevy to children aged 2 and up with sickle cell disease or beta thalassemia

Canonical page: https://technooptimist.io/stories/fda-extends-casgevy-to-children-aged-2-and-up-with-sickle-cell-disease-9ed5c7a6
Date: 1 Jul 2026
About: [CRISPR Therapeutics](https://technooptimist.io/companies/crispr-therapeutics.md) · [Casgevy (exa-cel)](https://technooptimist.io/biotech/casgevy.md)
Original source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease

The FDA widened Casgevy's approval from age 12 down to age 2, the first gene therapy for sickle cell disease in children this young. In trials of children aged 5 to 11, all 8 sickle cell patients assessed went a year without severe pain crises and 8 of 9 beta thalassemia patients stopped needing transfusions. The review took 53 days under a priority voucher.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.